1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Altimmune Regains Some Momentum

 
• By Elizabeth Cairns

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.  

Newton's Cradle Momentum
• Source: Leigh Prather / Alamy Stock Photo

Updated results of the Phase II MOMENTUM trial of Altimmune Inc.’s obesity candidate pemvidutide have allowed the company to regain some of the ground it lost in March when an earlier cut from the same study revealed worryingly high discontinuations.

Key Takeaways
  • Updated data on Altimmune’s GLP-1/glucagon co-agonist pemvidutide are better than an earlier cut

The new data reveal improved efficacy and lower discontinuations, and Altimmune’s shares opened up by 83% at $5.80 on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.